SteelPeak Wealth LLC Has $699,000 Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

SteelPeak Wealth LLC grew its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 129.4% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,253 shares of the company’s stock after buying an additional 5,784 shares during the quarter. SteelPeak Wealth LLC’s holdings in CRISPR Therapeutics were worth $699,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Foguth Wealth Management LLC. acquired a new position in shares of CRISPR Therapeutics in the 1st quarter valued at $1,008,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of CRISPR Therapeutics by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 16,876 shares of the company’s stock worth $1,150,000 after purchasing an additional 411 shares during the last quarter. Lincoln Capital Corp bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $204,000. Thrive Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $211,000. Finally, Wealthcare Advisory Partners LLC grew its holdings in shares of CRISPR Therapeutics by 7.7% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 4,200 shares of the company’s stock worth $286,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 2.5 %

Shares of NASDAQ:CRSP traded down $1.37 during trading on Friday, hitting $54.01. 1,313,469 shares of the company’s stock were exchanged, compared to its average volume of 1,370,108. CRISPR Therapeutics AG has a 1-year low of $37.55 and a 1-year high of $91.10. The firm has a 50-day moving average price of $56.72 and a two-hundred day moving average price of $64.53. The firm has a market cap of $4.59 billion, a P/E ratio of -19.86 and a beta of 1.78.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. During the same period last year, the company posted ($0.67) EPS. CRISPR Therapeutics’s revenue for the quarter was down 99.5% compared to the same quarter last year. As a group, research analysts predict that CRISPR Therapeutics AG will post -5.51 EPS for the current year.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now owns 208,122 shares of the company’s stock, valued at $12,468,589.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on CRSP. Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Friday. Wells Fargo & Company lowered their target price on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an “equal weight” rating on the stock in a report on Thursday, May 9th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Citigroup decreased their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 23rd. Finally, Robert W. Baird raised their price objective on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a research report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $75.71.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.